Screener
BioCryst Pharmaceuticals BCRX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
FAQ
- What is BioCryst Pharmaceuticals's retained earnings?
- BioCryst Pharmaceuticals (BCRX) reported retained earnings of -$2.15B in Q2 2026.
- How has BioCryst Pharmaceuticals's retained earnings changed year-over-year?
- BioCryst Pharmaceuticals's retained earnings decreased by 21.8% year-over-year, from -$1.76B to -$2.15B.
- What is the long-term trend for BioCryst Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's retained earnings has grown at a 8.0% compound annual growth rate (CAGR), from -$1.02B to -$1.51B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about BioCryst Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude